AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 141 min read$TLX

Telix (TLX) CFO lifts personal holding to 13,992 shares

Telix Pharmaceuticals Ltd's (TLX) Group CFO, Darren Charlton Smith, acquired 2,071 ordinary shares at 9.656 AUD each under the company's employee share purchase plan, increasing his direct holdings to 13,992 shares.

Original reporting
stocktitan.net
Published Sep 14, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TLX
Neutral
high confidence
Mentioned
$TLX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TLXNeutralLow
01

Why it matters

The CFO's modest buy may be viewed as a confidence signal but unlikely to move the stock.

02

Market read

Low relevance; small insider purchase with limited market impact.

03

What to watch

Potential dilution from ESPP allocations and overall insider activity not disclosed.

Relevance 4/10Novelty 4/10Timing: reported after the September 7 purchase

Background

Form 4 filing discloses insider transactions; CFO's purchase is part of an employee share plan.

Company-level read

Ticker impact

$TLXNeutralHigh confidence
Context

CFO Darren Charlton Smith bought 2,071 shares at A$9.656, raising his holding to 13,992 shares.

Expected impact

little to no immediate effect; may support slight upside bias.

Evidence & confidence

Purchase size (~$20k) is trivial relative to market cap; insider buying is a modest positive signal.

Market effects

Sector

None significant for biotech sector.

Regional

Limited to Australian‑listed investors.

Global

Minimal.

Counterpoint

What could challenge this read

Insider purchase could be a routine compensation event, not a strong endorsement.

Key entities

  • person
    Darren Charlton Smith

    Group Chief Financial Officer of Telix Pharmaceuticals

Read at source← All news

Related articles

SEP 15
$TLXHighAI 8/10

Buy, hold, sell: Domino's Pizza, Telix Pharmaceuticals, Westfarmers shares

Telix Pharmaceuticals (TLX) shares surged 10% to $17.99 after FDA approval for its brain cancer imaging drug, Pixclara, with analysts seeing 37% upside. Domino's Pizza (DMP) shares rose 1% to $19.14 despite a 11.2% revenue drop and $134.2M loss, with brokers suggesting a hold. Wesfarmers (WES) shares fell 0.5% to $72.42 after a mixed FY26 report, with most analysts recommending a sell.

fool.com.au3 min
SEP 14
$TLXHighAI 9/10

New FDA-approved brain cancer scan from Telix Pharmaceuticals (TLX) helps doctors see a key difference

Telix Pharmaceuticals (TLX) received FDA approval for Pixclara, a PET imaging drug for brain cancer (glioma). It's the first FDA-approved FET-PET imaging drug, addressing a significant unmet need in the U.S. Pixclara helps differentiate recurrent glioma from treatment-related changes, improving diagnostic accuracy. Telix is a commercial-stage radiopharmaceutical company with a portfolio of precision diagnostics and therapeutics.

stocktitan.net2 min
SEP 14
$TLXHighAI 9/10

Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children

Telix Pharmaceuticals (TLX) announced FDA approval for Pixclara, a PET imaging drug for glioma. Pixclara is the first FDA-approved FET-PET imaging drug in the U.S. and is indicated for adults and pediatric patients. The approval may expand U.S. access to FET-PET imaging and support diagnosis and treatment planning. TLX stock closed at $11.29 on Friday and is up 8.95% in pre-market trading.

rttnews.com2 min
SEP 14
$TLXHighAI 9/10

FDA approves Telix’s first FET-PET imaging drug for glioma

The FDA approved Telix Pharmaceuticals' Pixclara, the first FDA-approved FET-PET imaging drug for glioma. It helps differentiate glioma progression from treatment-related changes. Telix aims to expand its precision medicine platform into brain cancer, with Pixclara targeting amino acid transporters in glioma tissue. The approval addresses a significant unmet need in brain cancer imaging.

manufacturingchemist.com3 min
SEP 14
$TLXHighAI 8/10

Lunch Wrap: Telix gets the FDA tick as oil price spoils ASX mood

The ASX 200 was flat at lunchtime on Monday. Telix Pharmaceuticals (TLX) shares rose 4% after the FDA approved its PET imaging drug for glioma brain cancer. Other movers: Cleanaway (CWY) +4%, FleetPartners (FPR) +10%, REA Group (REA) in focus after ACCC contract changes. Oil prices surged above $107 due to Middle East tensions and a likely Fed rate hike.

stockhead.com.au2 min